Verastem Oncology, a biopharmaceutical company focused on RAS/MAPK pathway-driven cancers, is set to participate in several investor conferences in May. The company will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20 at 12:00 pm ET, and the 2025 RBC Capital Markets Global Healthcare Conference on the same day at 3:35 pm ET. They will also join the Alliance Global Partners/A.G.P.'s Annual Healthcare Company Showcase for a virtual chat on May 21 at 10:20 am ET.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。